First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias.
The MightyMedic (Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast) Working Group has been founded in 2013. The leading idea was to establish an international network of interdisciplinary nature aimed at working to cross national borders research projects, clinical trials, educational initiatives (meetings, workshops, summer schools) in the field of metabolic diseases, namely hyperlipidemias, and diabetes, preventive cardiology, and atherosclerosis. Therapeutic apheresis, its indications and techniques, is a parallel field of investigation. The first on-line survey of the Group has been completed in the first half of 2014. The survey included # 24 Centers in Italy, Germany, Greece, UK, Sweden, Japan and USA. Relevant data have been collected on current practice in diagnosis, therapy and follow-up of dyslipidemias. 240 subjects with hyperlipidemia and treated with lipoprotein apheresis have been reported in the survey, but a large percentage of patients (35%) who could benefit from this therapeutic option are still treated by conventional drug approach. Genetic molecular diagnosis is performed in only 33% of patients while Lipoprotein(a) (Lp(a)) is included in cardiovascular disease risk assessment in 71% of participating Centers. New detailed investigations and prospective multicenter studies are needed to evaluate changes induced by the impact of updated indications and strategies, as well as new treatment options, targeting standardization of therapeutic and diagnostic approaches.
Extracorporeal Therapeutic Techniques Unit - Lipid Clinic and Atherosclerosis Prevention Centre, Department of Molecular Medicine, 'Sapienza' University of Rome, 'Umberto I' Hospital, Rome, Italy. Electronic address: claudia.stefanutti@uniroma1.it.
C
C
Stefanutti
Immunohematology and Transfusion Medicine, ASL3, Pistoia, Italy.
G
G
D'Alessandri
Kaneka Pharma Europe NV, Brussels, Belgium.
A
A
Petta
National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
M
M
Harada-Shiba
Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany.
U
U
Julius
University Department of Medicine, Central Manchester Foundation Trust, Manchester, United Kingdom.
H
H
Soran
Department of Internal Medicine, Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, KS, USA.
P M
PM
Moriarty
Sahlgrenska Academy at University of Gothenburg, Department of Molecular and Clinical Medicine, Gothenburg, Sweden.
S
S
Romeo
1st Department of Paediatrics Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece.
E
E
Drogari
Lipid Center Nordrhein, Mülheim an der Ruhr, Germany.
B R
BR
Jaeger
D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal / Q000639:trends*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D003299:Cooperative Behavior; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D019983:Guideline Adherence / Q000639:trends; D019538:Health Care Surveys; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007391:International Cooperation; D020407:Internet; D008055:Lipids / Q000097:blood*; D025202:Molecular Diagnostic Techniques / Q000639:trends; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends*; D011237:Predictive Value of Tests; D012307:Risk Factors; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D000960:Hypolipidemic Agents; D008055:Lipids
Coronary artery disease; Dyslipidemia; Lipoprotein apheresis; Multicenter study; Survey